PID

Invesco International Dividend Achievers ETF · NAS

Category Equity
Expense Ratio 0.53%
Listing Date Sep 15, 2005
Volume 165,252.0
Market Cap (AUM) $811.44M

Performance

-3.62%

-3.55%

-6.37%

+5.42%

+2.76%

YTD

+5.25%

Top Holdings

Name
Symbol
%Assets
Atlantica Sustainable Infrastructure plcAY4.97%
Brookfield Renewable Partners LPBEP.UT4.47%
British American Tobacco PLC Sponsored ADRBTI4.28%
PLDT, Inc. Sponsored ADRPHI4.26%
Enbridge Inc.ENB4.10%
Canadian Imperial Bank of CommerceCM4.03%
TC Energy CorporationTRP3.92%
Brookfield Infrastructure Partners L.P.BIP3.79%
TELUS CorporationT3.66%
BCE Inc.BCE3.59%

Advanced Technical Analysis

Technical Analysis of PID 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. The Technical Score of 33 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Recent News & Updates

2021-08-11 06:41
BAM Option Traders Banking on Earnings Rise(Investopedia)
2020-02-07 01:30
Is Recession Knocking at the Door? ETF Strategies to Follow(Yahoo Finance)
2020-01-20 19:33
Economic Slowdown in 2020? ETF Strategies to Help You(Yahoo Finance)
2019-08-15 20:00
5 High-Dividend ETFs Available Under $20(Yahoo Finance)
2019-04-15 20:00
4 ETF Strategies to Follow Amid Global Growth Slowdown(Yahoo Finance)
2018-03-05 22:03
7 Intelligent International Dividend ETFs for Blue-Chip Income(Yahoo Finance)
2018-02-05 19:10
Dividend plays on slippery ground as bond yields steepen(Yahoo Finance)
2018-01-25 18:30
How Is Novartiss Subsidiary Sandoz Positioned for 2018?(Marketrealist)
2018-01-21 22:30
Behind Novartiss 4Q17 Estimates: Innovative Medicines(Marketrealist)
2017-11-14 00:05
Behind Sanofis 3Q17 Revenue Growth(Marketrealist)
2017-09-13 21:19
The Zacks Analyst Blog Highlights: SDIV, DWX, LVL, FGD and PID(Yahoo Finance)
2017-09-13 21:07
How TEVAs CNS Drugs Performed in 1H17(Marketrealist)
2017-09-13 01:27
5 Hot Global Dividend ETFs(Yahoo Finance)
2017-09-12 22:37
How TEVAs Generic Medicines Franchise Is Positioned after 1H17(Marketrealist)
2017-09-11 00:32
How ONEOK Has Managed Its Impressive Dividend Yield(Marketrealist)
2017-08-30 06:06
What Happened to Novartiss Innovative Medicines Business in 2Q17?(Marketrealist)
2017-08-30 02:11
Global Dividend Payments Upbeat in Q2: ETFs to Benefit(Yahoo Finance)
2017-08-23 00:42
Dividend Yield of Stanley Black & Decker(Marketrealist)
2017-08-17 22:37
A Look at Sanofi Pasteurs Performance in 2Q17(Marketrealist)
2017-08-17 19:37
North America: Fresenius Medical Cares Major Target Market in 2017(Marketrealist)
2017-08-16 21:07
Sanofi Genzyme Continues Driving Revenue Growth in 2Q17(Marketrealist)
2017-08-15 21:32
Kimberly-Clarks Dividend Growth(Marketrealist)
2017-07-24 19:39
Novartis in 2Q17: Performance of Sandoz(Marketrealist)
2017-07-17 00:05
Analysts Expect Novartiss Revenues to Fall in 2Q17(Marketrealist)
2017-06-12 22:36
What Makes This Global Dividend Income ETF So Popular(Yahoo Finance)
2017-05-31 21:09
Inside Novartiss Segment-Wise Performance in 1Q17(Marketrealist)
2017-05-28 21:06
Performance of Sanofis Established Prescription Products in 1Q17(Marketrealist)
2017-05-02 00:00
Don't Sell, Buy 4 High Dividend ETFs Under $20 in May(Yahoo Finance)
2017-05-01 21:07
How GlaxoSmithKlines Vaccines Business Performed in 1Q17(Marketrealist)
2017-04-30 19:40
How GlaxoSmithKlines Business Segments Performed in 1Q17(Marketrealist)
2017-04-27 05:05
Novartiss 1Q17 Earnings: Innovative Medicines Segment(Marketrealist)
2017-04-25 19:36
GlaxoSmithKlines 1Q17 Estimates: Vaccines Business(Marketrealist)
2017-04-23 22:37
Analyst Ratings and Recommendations for Novartis(Marketrealist)
2017-04-21 01:13
Analyst Estimates for Novartiss 1Q17 Earnings(Marketrealist)
2017-04-03 19:36
Novartis Expects to Restore Alcons Profitability in the Future(Marketrealist)
2017-04-02 19:37
Sanofi Genzyme Continued Growth in 2016(Marketrealist)
2017-03-29 22:36
Reduced Co-pays May Boost Demand for Entresto(Marketrealist)
2017-03-29 19:36
Performance of GlaxoSmithKlines Vaccines Business in 2016(Marketrealist)
2017-03-28 19:37
GlaxoSmithKlines Pharmaceuticals Segment Performance(Marketrealist)
2017-03-28 02:56
With low yields abroad, investors hunt for international dividend funds(Marketwatch)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.